The patient was treated with ceftriaxone 2 gm IV daily for 28 days.
She underwent emergency laminectomy for decompression and was treated with ceftriaxone 2 gm IV daily for 28 days.
She was treated supportively with broad-spectrum antibiotics (meropenem) and granulocyte macrophage colony-stimulating factor (GM-CSF).
To examine the role of SRs in phagocytosis of S. aureus, adherent GM-MФs were treated with the SR blocker poly(I) or the control polyanion chondroitin sulfate prior to and during incubation with a panel of S. aureus strains.
To investigate the contribution of cytoskeleton and signaling pathways in phagocytosis of S. aureus, adherent GM-MФs were treated with a panel of inhibitors (table 1), or appropriate control vehicle solutions, prior to and during incubation with a panel of S. aureus strains as well as unopsonized latex beads, and analyzed by scanning cytometry as described in methods.
Likewise, GM-CSF-DCs were treated with neutralizing antibodies to RANTES or IP-10 prior to BCG infection.
In some experiments, day 4 bone marrow DC from BALB/c mice, cultured in GM-CSF/IL-4, were treated with LF (0.1, 1 or 10 μg/ml) or PBS, and fresh medium without LF was added every 24 hours.
To determine whether E2 influenced ERα mRNA expression at earlier time points, GM-CSF-matured macrophages were treated with E2 or vehicle control, and ERα message was measured over the course of 72 hours (Figure 2E).
GM-MФs in suspension were treated with 10 µg/ml poly(I) or chondroitin sulfate, and incubated with S. aureus (commercial killed Wood or RN6390 strain) or green fluorescent latex beads and analyzed by flow cytometry.
To generate DC-like cells (DCLCs), THP-1 cells were treated with GM-CSF and IL-4 (GM-CSF/IL-4) [ 40- 44] at the indicated concentrations for up to 6 to 12 days.
